TY - JOUR
T1 - Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
AU - Kolesar, Jill
AU - Huang, Wei
AU - Eickhoff, Jens
AU - Hahn, Kristine
AU - Alberti, Dona
AU - Attia, Steven
AU - Schelman, William
AU - Holen, Kyle
AU - Traynor, Anne
AU - Ivy, Percy
AU - Wilding, George
N1 - Funding Information:
Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).
PY - 2009/6
Y1 - 2009/6
N2 - Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.
AB - Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.
KW - 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone
KW - Automated quantitative immunohistochemistry (AQUA)
KW - Quantitative real time PCR
KW - Ribonucleotide reductase
KW - Triapine
UR - http://www.scopus.com/inward/record.url?scp=67349119922&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349119922&partnerID=8YFLogxK
U2 - 10.1007/s00280-008-0845-0
DO - 10.1007/s00280-008-0845-0
M3 - Article
C2 - 18941749
AN - SCOPUS:67349119922
SN - 0344-5704
VL - 64
SP - 79
EP - 86
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 1
ER -